Revenue increased 445% compared with Q1 2020, with acquisitions of MVE Biological Solutions and CRYOPDP driving significant growth
- Organic revenue growth of 35% compared with Q1 2020
- A record 543 clinical trials in regenerative medicine are supported by Cryoport
- Cryoport now supports seven commercial therapies, including bluebird bio's and Bristol Myer Squibb's CAR-T therapy Abecma® and Bristol Myers Squibb's BREYANZI®
https://finance.yahoo.com/news/cryoport-revenue-climbs-53-3-200500829.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.